Abstract
Acquired thrombotic thrombocytopenic purpura (aTTP) is an acute life-threatening disease where mortality rates are critical outcomes. Caplacizumab has been included as part of the treatment of aTTP along with plasma exchange and immunosuppression. The objective was to determine health outcomes and costs avoided in the treatment of an aTTP episode with caplacizumab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have